Search research articles
Contact Us
Filters
Showing results (61-70 of 106) with videos related to
Page
of 11
Sort By:
Der Urologe. Ausg. A
|
June 18, 2015
[Adjuvant radiotherapy in lymph-node-positive prostate cancer with low tumor burden after radical prostatectomy : Multicenter randomized phase III trial on the effect of adjuvant radio therapy in patients with prostate cancer with or without positive margins after radical prostatectomy (RP) and lymph node metastasis with low tumor burden (micrometastases, ≤ 2 lymph node macrometastases). ART-2 trial AP 61/11 of the AUO]
H Rexer, D Bartkowiak
Der Urologe. Ausg. A
|
March 3, 2004
[Radiotherapy versus radiotherapy plus hormone therapy in the case of isolated PSA increase after radical prostatectomy. A prospective multicenter Phase III study of the AUO (AP 26/99) and the ARO (00/01)]
R Schwarz, H Rexer
Der Urologe. Ausg. A
|
November 25, 2016
[Questionnaire study for patients with low-risk prostate cancer : Therapy decision and coping strategies after a diagnosis of low-risk prostate cancer (COPCa) - study AP 91/15 from the AUO]
H Rexer, C Wülfing
Aktuelle Urologie
|
July 30, 2020
H Rexer, P Hammerer
Der Urologe. Ausg. A
|
March 25, 2015
[Comparison of four treatment options for low-risk prostate cancer: Preference-based randomized study for the evaluation of four treatment modalities in prostate cancer with low or "early intermediate" risk (PREFERE) - trial AP 65/11 of the AUO]
H Rexer, R Bussar-Maatz
Eukaryotic Cell
|
June 26, 2007
Lia1p, a novel protein required during nuclear differentiation for genome-wide DNA rearrangements in Tetrahymena thermophila
Charles H Rexer, Douglas L Chalker
Aktuelle Urologie
|
February 8, 2019
H Rexer, M Retz, C Waller
Aktuelle Urologie
|
February 1, 2021
H Rexer, C Gratzke, M Graefen
Aktuelle Urologie
|
February 1, 2021
H Rexer, M Retz, M Kramer
Aktuelle Urologie
|
June 3, 2020
[A Phase 2, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated and Advanced (unresectable or metastatic) non-clear Cell Renal Cell Carcinoma - SUNNIFORECAST AN 41/16 der AUO]
H Rexer, L Bergmann, T Steiner
Page
of 11
Search research articles
Search
Showing results (61-70 of 106) with videos related to
Sort By:
Page
of 11
Der Urologe. Ausg. A
|
June 18, 2015
[Adjuvant radiotherapy in lymph-node-positive prostate cancer with low tumor burden after radical prostatectomy : Multicenter randomized phase III trial on the effect of adjuvant radio therapy in patients with prostate cancer with or without positive margins after radical prostatectomy (RP) and lymph node metastasis with low tumor burden (micrometastases, ≤ 2 lymph node macrometastases). ART-2 trial AP 61/11 of the AUO]
H Rexer, D Bartkowiak
Der Urologe. Ausg. A
|
March 3, 2004
[Radiotherapy versus radiotherapy plus hormone therapy in the case of isolated PSA increase after radical prostatectomy. A prospective multicenter Phase III study of the AUO (AP 26/99) and the ARO (00/01)]
R Schwarz, H Rexer
Der Urologe. Ausg. A
|
November 25, 2016
[Questionnaire study for patients with low-risk prostate cancer : Therapy decision and coping strategies after a diagnosis of low-risk prostate cancer (COPCa) - study AP 91/15 from the AUO]
H Rexer, C Wülfing
Aktuelle Urologie
|
July 30, 2020
H Rexer, P Hammerer
Der Urologe. Ausg. A
|
March 25, 2015
[Comparison of four treatment options for low-risk prostate cancer: Preference-based randomized study for the evaluation of four treatment modalities in prostate cancer with low or "early intermediate" risk (PREFERE) - trial AP 65/11 of the AUO]
H Rexer, R Bussar-Maatz
Eukaryotic Cell
|
June 26, 2007
Lia1p, a novel protein required during nuclear differentiation for genome-wide DNA rearrangements in Tetrahymena thermophila
Charles H Rexer, Douglas L Chalker
Aktuelle Urologie
|
February 8, 2019
H Rexer, M Retz, C Waller
Aktuelle Urologie
|
February 1, 2021
H Rexer, C Gratzke, M Graefen
Aktuelle Urologie
|
February 1, 2021
H Rexer, M Retz, M Kramer
Aktuelle Urologie
|
June 3, 2020
[A Phase 2, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated and Advanced (unresectable or metastatic) non-clear Cell Renal Cell Carcinoma - SUNNIFORECAST AN 41/16 der AUO]
H Rexer, L Bergmann, T Steiner
Page
of 11